Over the course of three decades of study, the deubiquitinase Herpesvirus associated
Ubiquitin-Specific Protease/Ubiquitin-Specific Protease 7 (HAUSP/USP7) has gradually …

Protein kinase inhibitors are potent anticancer therapeutics. For example, the Bcr-Abl kinase
inhibitor imatinib decreases mortality for chronic myeloid leukemia by 80%, but 22 to 41% of …

As the volume of publications rapidly increases, searching for relevant information from the
literature becomes more challenging. To complement standard search engines such as …

Chronic myelogenous leukemia (CML) is a clonal malignancy of hematopoietic stem cells
featured with the fusion protein kinase BCR-ABL. To elicit the mechanism underlying BCR …

Mutations in the drug binding region of BCR-ABL lead to imatinib resistance during the
management of chronic myeloid leukemia (CML). In our study, 62 Philadelphia positive …

There is a great demand to introduce new approaches into cancer treatment field due to
incidence of increased breast cancer all over the world. The current study was designed to …

Clinical effectiveness of imatinib mesylate in cancer treatment is compromised by its off-
target cardiotoxicity. In the present study, we have developed physically stable imatinib …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the
causative oncoprotein BCR-ABL1 (Breakpoint-cluster region/Abelson kinase), which is a …

A self-nanoemulsifying drug delivery system (SNEDDS) composed of ethyl oleate, Tween 80
and polyethylene glycol 600 was prepared as a new route to improve the efficacy of imatinib …

Chronic myeloid leukemia (CML) is a well-characterized oncological disease in which
virtually all patients possess a translocation (9; 22) that generates the tyrosine kinase BCR …